[HTML][HTML] ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers
SP Handattu, DW Garber, DC Horn, DW Hughes… - Journal of biological …, 2007 - ASBMB
Two homologous apoA-I mimetic peptides, 3F-2 and 3F 14, differ in their in vitro
antiatherogenic properties (Epand, RM, Epand, RF, Sayer, BG, Datta, G., Chaddha, M., and
Anantharamaiah, GM (2004) J. Biol. Chem. 279, 51404-51414). In the present work, we
demonstrate that the peptide 3F-2, which has more potent anti-inflammatory activity in vitro
when administered intraperitoneally to female apoE null mice (20 μg/mouse/day) for 6
weeks, inhibits atherosclerosis (lesion area 15,800±1000 μm 2, n= 29), whereas 3F 14 does …
antiatherogenic properties (Epand, RM, Epand, RF, Sayer, BG, Datta, G., Chaddha, M., and
Anantharamaiah, GM (2004) J. Biol. Chem. 279, 51404-51414). In the present work, we
demonstrate that the peptide 3F-2, which has more potent anti-inflammatory activity in vitro
when administered intraperitoneally to female apoE null mice (20 μg/mouse/day) for 6
weeks, inhibits atherosclerosis (lesion area 15,800±1000 μm 2, n= 29), whereas 3F 14 does …